Table 1.
Patient demographics, comorbidities, presence of pneumonia, treatment, and results of SARS-CoV-2 RT-PCR in the convalescent plasma by disease severity (n = 100).
| Disease severity |
|||
|---|---|---|---|
| Variables | Mild (n = 77, 77.0%) | Moderate (n = 19, 19.0%) | Severe (n = 4, 4.0%) |
| Demographics | |||
| Median age, years (range) | 45 (21–167) | 55 (31–67) | 63.5 (52–69) |
| Males | 40 (51.9%) | 16 (84.2%) | 2 (50.0%) |
| Comorbidities | |||
| Hypertension | 11 (14.3%) | 9 (47.4%) | 0 (0%) |
| Diabetes mellitus | 5 (6.5%) | 4 (2.1%) | 1 (25.0%) |
| Dyslipidemia | 11 (14.3%) | 6 (3.2) | 0 (0%) |
| Chronic obstructive pulmonary disease | 1 (0.01%) | 0 (0%) | 0 (0%) |
| Cardiovascular disease | 0 (0%) | 0 (0%) | 0 (0%) |
| Presence of pneumonia by imaging studies | 0 (0%) | 19 (100.0%) | 4 (100.0%) |
| Supportive therapy | |||
| Oxygen administration | 0 (0%) | 19 (100.0%) | 4 (100.0%) |
| Mechanical ventilation | 0 (0%) | 0 (0%) | 4 (100.0%) |
| ECMO | 0 (0%) | 0 (0%) | 2 (50.0%) |
| Medications | |||
| Steroid | 0 (0%) | 8 (42.1%) | 2 (50.0%) |
| Lopinavir/ritonavir | 0 (0%) | 2 (10.5%) | 2 (50.0%) |
| Favipiravir | 0 (0%) | 3 (15.8%) | 1 (25.0%) |
| Hydroxychloroquine | 0 (0%) | 5 (26.3%) | 0 (0%) |
| Remdesivir | 0 (0%) | 4 (21.1%) | 0 (0%) |
| Tocilizumab | 0 (0%) | 1 (10.5%) | 0 (0%) |
| Days from disease onset to the test (range) | 74 (21–167) | 65 (27–102) | 98.5 (57–162) |
| RT-PCR in the plasma | UND | UND | UND |
SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ECMO, extracorporeal membrane oxygenation; RT-PCR, real-time polymerase chain reaction; UND, undetected.